Pfizer Inc.

Oncology and Hematologic Malignancies

Breast cancer, non-small cell lung cancer, small cell lung cancer, prostate cancer, and colorectal cancer are central areas of interest, alongside studies in ovarian cancer, head and neck squamous cell carcinoma, esophageal cancer, hepatocellular carcinoma, and bladder cancer. Research also extends to blood cancers such as multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, acute lymphoblastic leukemia, and advanced lymphomas.

  • HER2-negative and hormone receptor-positive breast cancer
  • Advanced solid tumors
  • Relapsed or refractory multiple myeloma
  • Diffuse large B-cell lymphoma
  • Metastatic castration-resistant prostate cancer

Additional oncology work includes melanoma, non-muscle invasive bladder cancer, liposarcoma, and neuroblastoma, with a strong emphasis on advanced and metastatic disease settings.

Inflammatory and Autoimmune Disorders

Clinical research spans rheumatoid arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, idiopathic inflammatory myopathies, and juvenile idiopathic arthritis. The portfolio also includes immune-mediated skin and bowel diseases such as atopic dermatitis, alopecia areata, vitiligo, ulcerative colitis, Crohn’s disease, and eosinophilic esophagitis.

  • Atopic dermatitis
  • Vitiligo
  • Ulcerative colitis
  • Rheumatoid arthritis
  • Systemic lupus erythematosus

Other immune-focused studies address chronic spontaneous urticaria, hidradenitis suppurativa, and immune-mediated inflammatory disorders affecting skin, joints, and gastrointestinal tissues.

Hematology, Bleeding Disorders, and Cardiovascular Disease

Key hematology programs involve hemophilia A, hemophilia B, and primary immune thrombocytopenia, with attention to inherited bleeding disorders across pediatric and adult populations. Cardiovascular research includes heart failure, heart failure with preserved ejection fraction, and pulmonary arterial hypertension.

  • Hemophilia A
  • Hemophilia B
  • Primary immune thrombocytopenia
  • Heart failure with preserved ejection fraction
  • Pulmonary arterial hypertension

Additional areas include transthyretin amyloidosis and transthyretin amyloid cardiomyopathy, reflecting interest in rare cardiovascular and systemic protein-aggregation disorders.

Infectious Diseases and Vaccines

Pfizer’s infectious disease portfolio includes studies in COVID-19, RSV infection, pneumococcal infections, group B streptococcus disease, and serious gram-negative bacterial infections. Research also covers hospital-acquired pneumonia, ventilator-associated pneumonia, sepsis, and complicated urinary tract infection.

  • Respiratory syncytial virus
  • Group B streptococcus
  • Pneumococcal disease
  • Gram-negative bacterial infections
  • COVID-19

Vaccine-oriented work includes maternal and infant immunization studies, with emphasis on neonatal protection and prevention of invasive bacterial and respiratory infections.

Neurology, Metabolic, and Other Therapeutic Areas

Neurology studies focus on migraine, including chronic migraine, menstrual migraine, and migraine with or without aura, as well as prevention in adolescents. Metabolic and supportive-care research includes obesity, overweight management, type 2 diabetes mellitus, and cancer cachexia.

  • Migraine disorders
  • Obesity and overweight management
  • Type 2 diabetes mellitus
  • Cancer cachexia
  • Growth hormone deficiency

Other areas of interest include duchenne muscular dystrophy, IgA nephropathy, obesity-related appetite loss, and erosive esophagitis, showing breadth across neuromuscular, renal, gastrointestinal, and metabolic conditions.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Long-Term Safety of Dazukibart in Patients with Idiopathic Inflammatory Myopathies, Including Dermatomyositis and Polymyositis

    Recruiting

    3 1 1 1
    Bulgaria Hungary Italy Poland Spain Sweden
  • Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1
    Bulgaria Czechia Denmark Finland France Germany +8
  • Study on Rimegepant for Preventing Migraines in Children and Teens Aged 6 to 17

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland Spain
  • Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated diseases:
    Austria Belgium Czechia Denmark Finland France +6
  • Study on the Effects of PF-07275315 and PF-07264660 for Adults with Moderate to Severe Atopic Dermatitis

    Recruiting

    2 1
    Germany Poland
  • Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Austria Belgium Czechia Denmark Finland France +10